Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Lung Cancer (Amsterdam, Netherlands)|September 4, 2025
Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastasesJarno W J Huijs, Anna M Sadowska, Juliette H R J Degens, et al.European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2019
Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysisYvonne W S Jauw, Frederike Bensch, Adrienne H Brouwers, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2017
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid TumorsFrederike Bensch, Laetitia E Lamberts, Michaël M Smeenk, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2015
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PETMartha W den Hollander, Frederike Bensch, Andor W J M Glaudemans, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2024
Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast CancerBertha Eisses, Jasper J L van Geel, Adrienne H Brouwers, et al.Nature Medicine|November 28, 2018
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancerFrederike Bensch, Elly L van der Veen, Marjolijn N Lub-de Hooge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate TreatmentLaetitia E Lamberts, Catharina W Menke-van der Houven van Oordt, Eva J ter Weele, et al.JAMA Oncology|April 16, 2026
18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort TrialJasper J L van Geel, Bertha Eisses, Sjoerd G Elias, et al.Diagnostics (Basel, Switzerland)|February 24, 2024
Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast CancerJorianne Boers, Bertha Eisses, Mieke C Zwager, et al.Pageof 2